Welcome to our dedicated page for Talaris Therapeutics news (Ticker: tals), a resource for investors and traders seeking the latest updates and insights on Talaris Therapeutics stock.
Talaris Therapeutics, Inc. (Nasdaq: TALS) is a clinical-stage biotechnology leader developing novel cell therapies to transform treatment for organ transplant recipients and autoimmune disorders. This news hub provides investors with essential updates on corporate developments and research milestones.
Track key developments including merger activities with Tourmaline Bio, reverse stock split implementation, and progress of clinical programs targeting chronic immunosuppression reduction. Our curated news flow covers financial restructuring details, partnership announcements, and therapeutic pipeline updates.
Access verified information on strategic initiatives approved by shareholders, including the transition to trading as TRML post-merger. Stay informed about Tourmaline Bio’s TOUR006 program integration and its potential in treating thyroid eye disease through anti-IL-6 antibody development.
Bookmark this page for real-time updates on Talaris’ cell processing advancements and investor-related news. For comprehensive coverage of biotech innovations and corporate action analysis, revisit regularly as new information becomes available.
Talaris Therapeutics (TALS) announced financial results for Q1 2022. The company boasts a strong cash position of $225.5 million, up from $140.1 million year-over-year. R&D expenses significantly increased to $14.2 million, reflecting growth in clinical trials and personnel. The net loss widened to $18.3 million or $0.45 per share, compared to $9.3 million or $1.30 last year. The company will present multiple abstracts at the upcoming American Transplant Congress and plans updates on the FREEDOM-1 clinical trial.
Talaris Therapeutics (Nasdaq: TALS) has announced its data presentations at the upcoming American Transplant Congress (ATC), set for June 4-8, 2022. The company will present long-term follow-up findings from its Phase 2 study of FCR001, highlighting patient health outcomes compared to standard care. Key presentations include an oral update on urinary cell mRNA signatures in tolerant kidney transplant recipients and two posters discussing COVID-19 outcomes in the Phase 2 cohort. Talaris aims to advance cell therapies transforming organ transplantation care.
Talaris Therapeutics (TALS) reported promising results from its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) patients regarding COVID-19 outcomes. Of the 28 patients studied, 23 achieved durable chimerism and could discontinue immunosuppression. Among 18 vaccinated patients, only 11% tested positive for COVID-19, with no loss of chimerism or renal dysfunction. The study highlights a low infection rate and adequate antibody response in the cohort, indicating potential immunocompetence despite prior transplant challenges.
Talaris Therapeutics, Inc. (Nasdaq: TALS) announced the participation of its senior management team in two upcoming investor conferences. The first is the Morgan Stanley Healthcare Corporate Access Day on March 29, 2022, at the Boston Harbor Hotel, featuring 1x1 meetings. The second is a Guggenheim Virtual Genomic Medicines and Rare Disease Day on March 31, 2022, with a fireside chat at 3:00 p.m. ET. A live webcast of the Guggenheim event will be available on Talaris' website, with a replay accessible afterward. Talaris focuses on cell therapies for organ transplantation and immune disorders.
Talaris Therapeutics (TALS) reported strong advancements and financial results, including a cash balance of $244 million. The Phase 3 (FREEDOM-1) clinical trial is ongoing, showing promising results in kidney transplant patients who achieved drug-free immune tolerance. Phase 2 trials (FREEDOM-2 and FREEDOM-3) have begun in delayed tolerance and scleroderma, respectively. For the year ended December 31, 2021, net loss was $47.8 million ($1.64/share), with rising R&D expenses totaling $34.3 million.
Talaris Therapeutics (Nasdaq: TALS), a late-clinical stage cell therapy company, will have its CEO Scott Requadt present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 AM ET. The presentation will focus on therapies aimed at transforming the standard of care in solid organ transplantation and severe immune and blood disorders. A live webcast of this event will be available on Talaris’ website, with an archive accessible for 30 days post-event.
Talaris Therapeutics, Inc. (TALS), a late-clinical stage cell therapy company, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET. CEO Scott Requadt will lead this presentation, which aims to highlight Talaris's innovative therapies for solid organ transplantation and severe immune and blood disorders. A live webcast of the event will be available on Talaris's investor webpage, remaining accessible for 30 days post-event.
BOSTON and LOUISVILLE, Ky., Jan. 4, 2022 – Talaris Therapeutics (Nasdaq: TALS), a late-clinical stage cell therapy company, announced that CEO Scott Requadt will present at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The pre-recorded presentation will be available starting at 7:00 AM ET on January 10 on Talaris' website, where it will remain archived for 90 days. Talaris focuses on developing therapies aimed at revolutionizing treatment for solid organ transplantation and severe immune and blood disorders.
Talaris Therapeutics has been officially added to the NASDAQ Biotechnology Index as of December 20, 2021. This notable inclusion recognizes Talaris as a late-stage cell therapy company, developing innovative treatments for solid organ transplants and severe autoimmune diseases. The NASDAQ Biotechnology Index tracks biotechnology and pharmaceutical companies listed on the NASDAQ exchange, serving as a benchmark for the iShares NASDAQ Biotechnology Index Fund. Inclusion in this index may enhance Talaris's visibility and attract more investor interest.
Talaris Therapeutics (Nasdaq: TALS) announced a promising analysis revealing that FCR001 induced durable immune tolerance in living donor kidney transplant recipients despite significant HLA mismatches. The study focused on 32 donor/recipient pairs in a Phase 2 trial, demonstrating that 25 subjects could fully withdraw immunosuppression up to 11 years post-treatment. The data was presented by Dr. Joseph R. Leventhal at the ASH Annual Meeting. Talaris aims to leverage these findings in its ongoing Phase 3 registrational study, FREEDOM-1.
